Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
eLife · 2023
DOI: 10.7554/elife.81801 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Barnaby Flower und 28 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Background
World Health Organization has called for research into predictive factors for selecting persons who could be successfully treated with shorter durations of direct-acting antiviral (DAA) therapy for hepatitis C. We evaluated early virological response as a means of shortening treatment and explored host, viral and pharmacokinetic contributors to treatment outcome.
Methods
Duration of sofosbuvir and daclatasvir (SOF/DCV) was determined according to day 2 (D2) virologic response for HCV genotype (gt) 1- or 6-infected adults in Vietnam with mild liver disease. Participants received 4- or 8-week treatment according to whether D2 HCV RNA was above or below 500 IU/ml (standard duration is 12 weeks). Primary endpoint was sustained virological response (SVR12). Those failing therapy were retreated with 12 weeks SOF/DCV. Host IFNL4 genotype and viral sequencing was performed at baseline, with repeat viral sequencing if virological rebound was observed. Levels of SOF, its inactive metabolite GS-331007 and DCV were measured on days 0 and 28.
Results
Of 52 adults enrolled, 34 received 4 weeks SOF/DCV, 17 got 8 weeks and 1 withdrew. SVR12 was achieved in 21/34 (62%) treated for 4 weeks, and 17/17 (100%) treated for 8 weeks. Overall, 38/51 (75%) were cured with first-line treatment (mean duration 37 days). Despite a high prevalence of putative NS5A-inhibitor resistance-associated substitutions (RASs), all first-line treatment failures cured after retreatment (13/13). We found no evidence treatment failure was associated with host IFNL4 genotype, viral subtype, baseline RAS, SOF or DCV levels.
Conclusions
Shortened SOF/DCV therapy, with retreatment if needed, reduces DAA use in patients with mild liver disease, while maintaining high cure rates. D2 virologic response alone does not adequately predict SVR12 with 4-week treatment. Funding: Funded by the Medical Research Council (Grant MR/P025064/1) and The Global Challenges Research 70 Fund (Wellcome Trust Grant 206/296/Z/17/Z).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
- Department of Infectious Disease, Imperial College London, London, United Kingdom.
- Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
- MRC Clinical Trials Unit at UCL, University College London, London, United Kingdom.
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
- Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Faculty of Tropical Medicine, Bangkok, Thailand.
ORCID-Profile: Barnaby Flower, Joel Tarning, Evelyne Kestelyn, Guy E Thwaites, Ann Sarah Walker, Jeremy N Day
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
Flower, B., Hung, L. M., Mccabe, L., Ansari, M. A., Le Ngoc, C., Vo Thi, T., Vu Thi Kim, H., Nguyen Thi Ngoc, P., Phuong, L. T., Quang, V. M., Dang Trong, T., Le Thi, T., Nguyen Bao, T., Kingsley, C., Smith, D., Hoglund, R. M., Tarning, J., Kestelyn, E., Pett, S. L., …, & Cooke, G. S. (2023). Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study. eLife. https://doi.org/10.7554/elife.81801
Vancouver
Flower B, Hung LM, Mccabe L, Ansari MA, Le Ngoc C, Vo Thi T, et al. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study. eLife. 2023. doi:10.7554/elife.81801
BibTeX
@article{Flower2023,
author = {Flower, Barnaby and Hung, Le Manh and Mccabe, Leanne and Ansari, M Azim and Le Ngoc, Chau and Vo Thi, Thu and Vu Thi Kim, Hang and Nguyen Thi Ngoc, Phuong and Phuong, Le Thanh and Quang, Vo Minh and Dang Trong, Thuan and Le Thi, Thao and Nguyen Bao, Tran and Kingsley, Cherry and Smith, David and Hoglund, Richard M and Tarning, Joel and Kestelyn, Evelyne and Pett, Sarah L and van Doorn, Rogier and Van Nuil, Jennifer Ilo and Turner, Hugo and Thwaites, Guy E and Barnes, Eleanor and Rahman, Motiur and Walker, Ann Sarah and Day, Jeremy N and Chau, Nguyen V V and Cooke, Graham S},
title = {Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.81801}
}
EUVIMED